Margenza Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing incidence of her2-positive breast cancer, expansion of oncology treatment centers, rising adoption of biologic cancer therapies, improvements in monoclonal antibody production, growing clinical awareness of targeted therapies.

The growth in the forecast period can be attributed to increasing development of next-generation antibody therapies, rising investments in precision oncology, expansion of home-based cancer care services, growing focus on treatment-resistant cancers, increasing demand for patient-specific biologic treatments. Major trends in the forecast period include increasing adoption of her2-targeted monoclonal antibodies, rising use of combination oncology therapies, growing focus on personalized cancer treatment regimens, expansion of advanced biologic manufacturing capabilities, enhanced emphasis on improved clinical outcomes.

The rising prevalence of HER2-positive breast cancer is anticipated to drive the growth of the margenza market in the coming years. HER2-positive breast cancer is a form of breast cancer characterized by cancer cells that express abnormally high levels of the HER2 protein on their surface. The increase in HER2-positive breast cancer is linked to improved detection and diagnostic capabilities through advanced screening technologies, along with genetic and environmental influences, an aging population, and hormonal and reproductive factors that may heighten vulnerability to this cancer subtype. Margenza is effective in treating HER2-positive breast cancer by specifically targeting and inhibiting the HER2 protein, thereby helping to slow or halt the growth of cancer cells that overexpress this protein. For instance, in July 2025, according to a study published in The International Journal of Molecular Sciences, a US-based international peer-reviewed scientific journal, approximately 2.3 million new breast cancer cases and 670,000 related deaths were reported among women worldwide in 2022, with projections suggesting that new cases and deaths will rise by 38% and 68%, respectively, by 2050. Consequently, the growing incidence of HER2-positive breast cancer is driving the clinical trial margenza market.

Increasing healthcare expenditure is anticipated to drive the expansion of the Margenza market in the coming years. Healthcare expenditure encompasses the overall financial resources allocated to medical services, treatments, and infrastructure, including both public and private spending on healthcare systems, equipment, and pharmaceuticals. The growth in healthcare spending is fueled by factors such as aging populations, advances in medical technology, a rising prevalence of chronic diseases, and increasing demand for high-quality healthcare services. Expanded healthcare budgets enable greater investment in advanced and specialized therapies, including targeted treatments such as Margenza. As governments, private insurers, and individuals dedicate more funds to healthcare, the accessibility and affordability of costly cancer therapies improve. For example, in September 2024, according to the Centers for Medicare & Medicaid Services, a US-based federal agency, U.S. healthcare spending rose by 4.1% in 2024, reaching $4.5 trillion, or $13,493 per person. Consequently, rising healthcare expenditure is expected to support the growth of the Margenza market.

In October 2024, TerSera Therapeutics, LLC, a US-based pharmaceutical company, acquired the rights to the breast cancer drug MARGENZA (margetuximab) from MacroGenics for an undisclosed sum. Through this acquisition, TerSera Therapeutics seeks to broaden its oncology portfolio and offer an additional treatment option for patients with HER2-positive breast cancer. MacroGenics is a US-based biotechnology company that develops and manufactures antibody-based cancer therapies, including MARGENZA (margetuximab-cmkb).

Major companies operating in the margenza market are MacroGenics Inc.

North America was the largest region in the margenza market in 2025. The regions covered in the margenza market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the margenza market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the margenza market by increasing costs of imported cell culture media, bioreactor components, purification resins, and cold-chain distribution materials required for monoclonal antibody production. Oncology treatment centers in North America and Europe are most affected due to dependence on globally sourced biologics manufacturing inputs, while Asia-Pacific faces cost pressures on export-oriented biologic production. These tariffs are contributing to higher therapy costs and tighter reimbursement environments. However, they are also driving domestic biologics manufacturing expansion, regional supply chain diversification, and increased investment in localized antibody production facilities.

The margenza market research report is one of a series of new reports that provides margenza market statistics, including margenza industry global market size, regional shares, competitors with a margenza market share, detailed margenza market segments, market trends and opportunities, and any further data you may need to thrive in the margenza industry. This margenza market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Margenza (margetuximab-cmkb) is a monoclonal antibody therapy that targets the human epidermal growth factor receptor 2 (HER2). It is approved for use in combination with chemotherapy to treat adult patients with metastatic HER2-positive breast cancer who have previously received two or more anti-HER2 treatment regimens, including at least one for metastatic disease.

The primary indications of Margenza include breast cancer and gastric cancer. Breast cancer is a form of cancer that develops in the breast cells, most commonly in the ducts or lobules, and may spread to other areas of the body if it is not identified and treated at an early stage. It is offered in different formulations, including intravenous infusion and subcutaneous injection. The drug is distributed through various channels such as hospitals, oncology clinics, and home healthcare services. Additionally, it is used by multiple end users, including adult patients and elderly patients.

The margenza market consists of sales of margenza (margetuximab) injection, combination therapies, and supportive care medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.